Mutations in the receptor tyrosine kinases (RTKs) FLT3 and KIT as well as the Ras family of oncogenes provide proliferative advantage for pre-leukemic clones and account for two-thirds of all AML mutations [8]. Here, FLT3 is linked to acute myeloid leukemia.